Bellerophon therapeutics, inc. (BLPH)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating expenses:
Research and development

2,238

2,839

3,259

2,629

2,305

2,817

5,247

5,815

6,380

5,390

4,438

4,689

3,337

5,111

2,472

3,954

5,113

8,329

7,090

8,426

9,520

9,610

11,559

12,769

12,040

General and administrative

1,872

1,476

1,332

1,596

2,037

1,867

1,584

2,058

2,112

1,919

1,746

1,634

1,446

2,181

1,745

1,205

1,976

2,533

4,329

3,435

4,573

3,177

3,934

4,194

2,470

Total operating expenses

4,110

4,315

4,591

4,225

4,342

4,684

6,831

7,873

8,492

7,309

6,184

6,323

4,783

7,292

4,217

5,159

7,089

10,862

11,419

11,861

14,093

12,787

15,493

16,963

14,510

Other operating income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

250

251

1,166

0

0

0

0

Loss from operations

-4,110

-4,315

-4,591

-4,225

-4,342

-4,684

-6,831

-7,873

-8,492

-7,309

-6,184

-6,323

-4,783

-7,292

-4,217

-5,159

-7,089

-10,862

-11,169

-11,610

-12,927

-12,787

-15,493

-16,963

-14,510

Change in fair value of common stock warrant liability

894

-178

-215

-673

-1,616

-3,676

-17,840

3,689

-7,050

16,948

1,435

-2,367

14,387

590

0

0

0

0

0

0

0

-

-

-

-

Warrant amendment charge

-

0

0

674

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income, net

34

57

89

121

130

96

92

91

99

98

33

26

27

21

22

22

30

36

27

27

19

18

13

48

0

Pre-tax loss

-4,970

-4,080

-4,287

-4,105

-2,596

-912

11,101

-11,471

-1,343

-24,159

-7,586

-3,930

-19,143

-7,861

-4,195

-5,137

-7,059

-10,826

-11,142

-11,583

-12,908

-12,769

-15,480

-16,915

-14,510

Income tax benefit

0

0

0

0

-1,801

0

0

0

-5,439

0

0

0

0

-438

0

0

0

0

0

0

0

0

0

0

0

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,826

-11,142

-11,583

-12,908

-12,769

-15,480

-16,915

-14,510

Net loss

-4,970

-4,080

-4,287

-4,105

-795

-

-

-

-

-

-

-

-

-7,423

-4,195

-5,137

-7,059

-

-

-

-

-

-

-

-

Weighted average shares outstanding:
Basic (in shares)

4,615

4,566

4,553

4,543

4,346

3,847

3,847

3,815

3,803

55,109

34,989

33,558

31,934

-

-

-

-

-

-

-

-

-

-

-

-

Diluted (in shares)

4,615

4,566

4,553

4,543

4,346

3,971

4,302

3,815

4,806

55,109

34,989

40,491

31,934

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

20,186

13,854

13,093

13,053

13,026

12,911

12,910

10,152

7,898

7,897

7,898

7,899

Net loss per share:
Basic (in usd per share)

-1.08

-0.89

-0.94

-0.90

-0.18

-0.24

2.89

-3.01

1.08

-0.44

-0.22

-0.12

-0.60

-

-

-

-

-

-

-

-

-

-

-

-

Diluted (in usd per share)

-1.08

-0.89

-0.94

-0.90

-0.18

-1.15

-1.55

-3.01

-0.60

-0.44

-0.22

-0.15

-0.60

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.37

-0.30

-0.39

-0.54

-0.83

-0.86

-0.90

-1.27

-1.62

-1.96

-2.14

-1.84